Isostructural metabolites of two anti-Parkinson drugs

被引：2
|
作者：
Simon, K
Harmat, V
Torok, Z
Bocskei, Z
Hermecz, I
机构：
[1] Chinoin Chem & Pharmaceut Works Ltd, Dept Preclin Dev, H-1325 Budapest, Hungary
[2] Eotvos Lorand Univ, Dept Theoret Chem, H-1518 Budapest, Hungary
来源：
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY | 1998年 / 54卷
关键词：
D O I：
10.1107/S0108270197019896
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The absolute configurations of desmethylselegiline hydrochloride [(R)-(-)-1-benzyl-N-(2-propynyl)ethylammonium chloride, C12H16N+.Cl-], (1), and p-fluorodesmethylselegiline hydrochloride [(R)-(-)-1-(4-fluorobenzyl)-N-(2-propynyl)ethylammonium chloride, C12H15FN+.Cl-], (2), have been determined. The two compounds are metabolites of the anti-Parkinson agent selegiline and its backup, p-fluoroselegiline. The two crystal structures are highly isostructural.
引用
收藏
页码：811 / 813
页数：3
相关论文
共 50 条
  • [31] Investigation of anti-Parkinson activity of dicyclomine
    Sanawar, Maham
    Saleem, Uzma
    Anwar, Fareeha
    Nazir, Samra
    Akhtar, Muhammad Furqan
    Ahmad, Bashir
    Ismail, Tariq
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2022, 132 (04) : 338 - 351
  • [32] Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing
    Chalorak, Pawanrat
    Jattujan, Prapaporn
    Nobsathian, Saksit
    Poomtong, Tanate
    Sobhon, Prasert
    Meemon, Krai
    NUTRITIONAL NEUROSCIENCE, 2018, 21 (06) : 427 - 438
  • [33] UTILIZATION OF ANTI-PARKINSON DRUGS IN NORWAY, SWEDEN, DENMARK AND FINLAND 1975-1979
    AQUILONIUS, SM
    GRANAT, M
    HARTVIG, P
    ACTA NEUROLOGICA SCANDINAVICA, 1981, 64 (01): : 47 - 53
  • [34] Prescribing Pattern of Anti-Parkinson Drugs in Japan: A Trend Analysis from 2005 to 2010
    Nakaoka, Sachiko
    Ishizaki, Tatsuro
    Urushihara, Hisashi
    Satoh, Toshihiko
    Ikeda, Shunya
    Yamamoto, Mitsutoshi
    Nakayama, Takeo
    PLOS ONE, 2014, 9 (06):
  • [35] Binding of Anti-Parkinson's Disease Drugs to Human Serum Albumin is Allosterically Modulated
    Fanali, Gabriella
    Rampoldi, Viviana
    di Masi, Alessandra
    Bolli, Alessandro
    Lopiano, Leonardo
    Ascenzi, Paolo
    Fasano, Mauro
    IUBMB LIFE, 2010, 62 (05) : 371 - 376
  • [36] Optimization of Parkinson Disease Treatment Combining Anti-Parkinson Drugs and Deep Brain Stimulation Using Patient Diaries
    Schneider, Jakub
    Novak, Daniel
    Jech, Robert
    2015 37TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2015, : 3444 - 3447
  • [37] An anti-parkinson botanical with symptomatic and neuroprotective effect
    Manyan, BV
    MOVEMENT DISORDERS, 2006, 21 : S113 - S113
  • [38] Anti-Parkinson's disease drug is withdrawn
    不详
    CHEMISTRY IN BRITAIN, 1999, 35 (02) : 10 - 10
  • [39] PHARMACOLOGY OF A POTENTIAL ANTI-PARKINSON AGENT - TIGLOIDINE
    SANGHVI, I
    BINDLER, E
    GERSHON, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1968, 4 (03) : 246 - &
  • [40] BRL 1288 - A NEW ANTI-PARKINSON DRUG
    BROWN, DM
    HUGHES, BO
    MEHTA, MD
    NATURE, 1969, 223 (5204) : 416 - &
12345